2025-10-19 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX) based on the provided data, structured in a way that provides both quantitative information and qualitative analysis.

## TG Therapeutics Inc. (TGTX) Analysis

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

---

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 83.02%
*   **VOO Cumulative Return:** 97.05%
*   **Absolute Divergence (Current):** -16.3
*   **Relative Divergence:** 20.8 (This indicates that the current divergence is in the lower range of its historical divergence, suggesting TGTX is currently underperforming VOO compared to its historical performance).

**Analysis:** TGTX has underperformed the S&P 500 (VOO) over the analyzed period. The negative absolute divergence highlights this underperformance. The relative divergence value suggests that the degree of underperformance is significant compared to its historical range, although it is not at the absolute lowest point.

**Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | -5.0%  | 73.5% | -33.0% | -0.0  | 1.3    |
| 2016-2018  | -12.0% | 73.5% | -27.0% | -0.0  | 0.7    |
| 2017-2019  | 74.0%  | 74.1% | 52.0%  | 0.0   | 1.8    |
| 2018-2020  | 316.0% | 74.1% | 293.0% | 0.1   | 8.2    |
| 2019-2021  | 124.0% | 74.1% | 78.0%  | 0.3   | 3.0    |
| 2020-2022  | -71.0% | 77.8% | -71.0% | -0.0  | 1.9    |
| 2021-2023  | -284.0%| 77.8% | -285.0%| -1.1  | 2.7    |
| 2022-2024  | 56.0%  | 77.8% | 36.0%  | -1.0  | 4.8    |
| 2023-2025  | 83.0%  | 80.7% | 22.0%  | -0.1  | 5.5    |

**Analysis of Alpha, Beta Table:**

*   **CAGR:** Fluctuates significantly, showing periods of high growth (e.g., 2018-2020) and substantial declines (e.g., 2021-2023). The high volatility makes it a risky investment.
*   **MDD:** High Maximum Drawdown across all periods indicates substantial risk.
*   **Alpha:** Periods with positive Alpha indicate outperformance relative to the market, while negative Alpha indicates underperformance. There are strong swings in Alpha, reflecting TGTX's volatile performance.
*   **Beta:** Mostly near zero or negative, suggesting TGTX is not strongly correlated with the market and has, at times, moved inversely to the market.
*   **Cap(B):** Market Cap varies over the years, peaking in 2018-2020.

### 2. Recent Stock Price Movements

*   **Current Price:** 34.67
*   **Previous Close:** 34.87
*   **Change:** -0.57
*   **5-Day Moving Average:** 34.59
*   **20-Day Moving Average:** 35.4162
*   **60-Day Moving Average:** 32.2435

**Analysis:** The current price is slightly below the previous close, indicating a minor recent decrease. The 5-day moving average is below the 20-day moving average, which is below the 60-day moving average. This suggests a potential short-term downward trend, although the price is hovering around the 5-day MA.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment - approaching Very Risky)
*   **RSI:** 34.87 (Approaching Oversold Territory)
*   **PPO:** -0.8469 (Slightly Bearish)
*   **Hybrid Signal:** Cash_80%_Sell - Suggests a strategy of selling 80% of holdings due to perceived risk.
*   **Recent (20-day) Relative Divergence Change:** -2.6 (Short-term Decline)
*   **Expected Return:** -109.6% (Significant Underperformance Predicted vs. S&P 500 Over 2+ Years)

**Analysis:**

*   The MRI indicates low investment recommendation (approaching very risky), reflecting caution.
*   The RSI value of 34.87 is close to the oversold territory (typically below 30), suggesting the stock *may* be undervalued in the short term, but requires further confirmation.
*   The negative PPO supports the bearish outlook.
*   The significant negative expected return indicates that, based on the model, long-term investment is projected to result in substantial underperformance compared to the S&P 500.
*   The minor negative change in price reflects a short-term downward trend, but it is not a dramatic change.

### 4. Recent News & Significant Events

*   **Positive News:** Recent news focuses on the positive 6-year safety data for BRIUMVI® in multiple sclerosis patients, showing a high percentage of patients free from disability progression. Institutional investors are also highlighted.
*   **Potential Issue:** News regarding "Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis" may be considered competition

**Analysis:** The news flow is largely positive, focusing on the long-term efficacy and safety of BRIUMVI®, a key drug for TGTX. This could attract long-term investors.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.78)
*   **Target Price:** Average 43.57 (Suggests potential upside)

**Analysis:** Despite the technical indicators and expected return suggesting caution, analyst opinions remain positive, with a "Buy" consensus and a target price significantly above the current price. This suggests analysts see potential for future growth, perhaps driven by the success of BRIUMVI®.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-08-08 | 0.19  | 0.14 B$   |
| 2025-05-09 | 0.03  | 0.12 B$   |
| 2024-11-07 | 0.03  | 0.08 B$   |
| 2024-08-09 | 0.05  | 0.07 B$   |
| 2025-08-08 | 0.05  | 0.07 B$   |

**Analysis:**

*   Recent EPS and revenue figures show growth. The most recent quarter (2025-08-08) shows a substantial increase in both EPS and revenue compared to prior periods.
*   The increasing revenue trend is a positive sign.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.14B  | 86.58%        |
| 2025-03-31   | $0.12B  | 87.14%        |
| 2024-12-31   | $0.11B  | 85.77%        |
| 2024-09-30   | $0.08B  | 88.86%        |
| 2024-06-30   | $0.07B  | 88.70%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE    |
|--------------|---------|--------|
| 2025-06-30   | $0.28B  | 10.20% |
| 2025-03-31   | $0.24B  | 2.13%  |
| 2024-12-31   | $0.22B  | 10.49% |
| 2024-09-30   | $0.19B  | 2.02%  |
| 2024-06-30   | $0.18B  | 3.87%  |

**Analysis:**

*   **Revenue & Profitability:** Revenue has consistently increased over the past five quarters. High-profit margins indicate efficient cost management or strong pricing power.
*   **Capital & Profitability:** Equity has grown, reflecting increasing company value. ROE is volatile but shows periods of strong return, indicating efficient use of equity to generate profit.

### 7. 종합 Analysis

**Summary:**

TGTX presents a mixed picture.

*   **Positives:** Recent earnings and financial data show strong revenue growth, high-profit margins, and increasing equity. Analyst consensus is "Buy," and recent news focuses on positive clinical data for BRIUMVI®.
*   **Negatives:** TGTX has underperformed the S&P 500. Technical indicators (MRI, PPO) suggest caution, and the model projects significant underperformance in the long term. The stock is approaching oversold territory, which could signal a potential short-term rebound, but also highlights current weakness.
*   **Risks:** High MDD and volatile CAGR underscore the speculative nature of the stock.
*   **Overall:**  TGTX is a high-risk, high-reward investment. While recent financial performance and analyst sentiment are positive, the technical indicators and historical performance warrant caution. Investors should carefully weigh their risk tolerance and conduct further due diligence before investing. The positive news around BRIUMVI® and potential market catalysts could drive future growth, but the stock remains volatile.
